Malignancy-Associated Sweet Syndrome

Introduction:

Malignancy-associated Sweet syndrome is a skin disorder. It is characterized by sudden onset of fever and causes pain at the affected site. The condition was first discovered by Dr. Robert Douglas Sweet in 1964. It is a blood-associated skin malignancy. The other name of malignancy-associated Sweet syndrome is paraneoplastic Sweet syndrome or Sweet syndrome. The common symptoms associated with the condition are fever, red to purple nodules or papules appearing on the skin, tenderness at the affected site, and malaise. The healthcare team, including dermatologists, oncologists, and nurses, helps optimize patient outcomes by timely diagnosis and intervention. The article discusses malignancy-associated Sweet syndrome, its causes, symptoms, diagnosis, treatment, and prevention.

What Is a Malignancy-Associated Sweet Syndrome?

Malignancy-associated Sweet syndrome is a type of rare skin disease that tends to spread into the blood. The nature of Sweet syndrome is paraneoplastic. The condition in which the immune system is triggered due to a cancerous tumor. The healthcare team, including dermatologists, hematologists, and oncologists, often collaborate and diagnose and manage the malignancy-associated Sweet syndrome.

What Are the Causes of Malignancy-Associated Sweet Syndrome?

The proper cause of the malignancy-associated Sweet syndrome is not fully known. However, underlying malignancy may trigger an immune response. The causes of malignancy-associated Sweet syndrome are as follows:

• Hematologic Malignancies: Malignancy-associated Sweet syndrome can be associated with blood or hematologic malignancies, such as acute myeloid leukemia (blood or bone marrow cancer), myeloproliferative disorders (blood cancer), and myelodysplastic syndromes (blood cancer).

• Immune Dysregulation: The abnormal activation of immune cells may lead to infiltration of neutrophils into the skin. The malignancy may trigger and activate immune cells.

• Other Tumors: It is the less common cause. Sometimes, the condition may be associated with other solid tumors, such as colon or breast cancers.

• Genetic Cause: It is the ongoing research to explore the genetic factors that may predispose people to the development of malignancy-associated Sweet syndrome.

What Are the Risk Factors of Malignancy-Associated Sweet Syndrome?

The risk factors of malignancy-associated Sweet syndrome are as follows:

• Age and Gender: The condition may affect people at any age, but it is commonly reported in adults. Some research studies suggest that malignancy-associated Sweet syndrome is highly prevalent in women.

• Previous History of Sweet Syndrome: People have previous episodes of Sweet syndrome, whether malignant or benign. There is an increased risk of getting the condition again.

• Immunosuppressive People: People with a pre-existing condition or treatments that may lead to immunosuppression may be associated with an increased risk of the malignancy-associated Sweet syndrome. People who are undergoing chemotherapy for cancer are at high risk of developing the condition.

• Medications: Certain medications, such as medications for hematologic disorders, can increase the risk of developing the condition.

What Are the Signs and Symptoms of Malignancy-Associated Sweet Syndrome?

Malignancy-associated Sweet syndrome may cause skin and systemic symptoms. The common signs and symptoms of the condition are as follows:

• Skin Lesions: Patients with the condition may develop nodules, plaques, or red to purple bumps on the skin. The patient may feel pain and tenderness. The location of the appearance of nodules or papules is the face, neck, trunk, and upper extremities.

• Fever: It is a common symptom experienced by all patients.

• Pain and Discomfort: The person may feel pain, tenderness, and discomfort in the affected areas.

• Neutrophil Infiltration: The sign can be seen on histopathological examination. It shows infiltration of neutrophils in the dermal area. There will be no evidence of infection.

• Systemic Symptoms: An individual with malignancy-associated Sweet syndrome may experience systemic symptoms, such as fever, malaise, and generalized weakness.

How Is Malignancy-Associated Sweet Syndrome Diagnosed?

The healthcare team, including dermatologists and oncologists, may diagnose the condition with clinical evaluation, investigation test, and skin biopsy. The diagnosis of malignancy-associated Sweet syndrome is described below:

• Clinical Evaluation: The healthcare provider may physically examine the patient and assess the patient's medical history, which includes the onset and progression of skin lesions and other associated symptoms, such as fever, malaise, and weakness.

• Skin Biopsy: The other diagnostic test is skin biopsy. The healthcare provider may take a small piece of tissue or skin from the affected area. The skin tissue is taken and sent to the laboratory for histopathological findings. The results show a dense infiltration of neutrophils in the dermal area without any sign of infection.

• Laboratory Tests: The healthcare provider may advise blood tests to assess the patient's health and find any abnormalities associated with malignancy. The blood tests, such as complete blood count and specific markers related to solid tumors, can be done to find the condition.

• Imaging Tests: The healthcare provider may advise Computed Tomography (CT) and X-rays to find and evaluate underlying malignancy.

• Bone Marrow Examination: The healthcare provider may advise bone marrow biopsy and aspiration only in cases of hematologic malignancies. These biopsies are done to assess the bone marrow involvement and confirm the presence of the condition, such as acute myeloid leukemia.

How Is Malignancy-Associated Sweet Syndrome Treated?

The treatment approaches for malignancy-associated Sweet syndrome are as follows:

• Skin Lesions Management: The healthcare provider may prescribe systemic corticosteroids, such as Prednisone, to manage skin lesions. It is the first-line treatment. It helps in reducing inflammation and other associated symptoms.

• Malignancy Treatment: The malignant form of Sweet syndrome can be managed by chemotherapy, radiation therapy, and surgery.

• Immunosuppressive Medications: The doctor may prescribe immunosuppressive medications, such as Dapsone. These are prescribed these medications to patients with autoimmune diseases.

• Non-Steroidal Anti-inflammatory Drugs (NSAIDs): The doctor may prescribe NSAIDs, such as Acetaminophen, to manage symptoms such as pain, fever, and malaise.

What Are the Preventive Measures for Malignancy-Associated Sweet Syndrome?

The strategies to prevent malignancy-associated Sweet syndrome are as follows:

• Take regular health check-ups or undergo regular health screenings for early detection, which can help in prompt intervention.

• Cancer screenings, such as colonoscopies, may help early detect the condition.

• Maintain a healthy lifestyle by regular physical activity, avoiding alcohol consumption, and avoiding tobacco.

• Take guidance from a healthcare provider on early diagnosis and monitoring of the condition.

Conclusion:

In conclusion, malignancy-associated Sweet syndrome is a rare skin condition that affects the face, neck, trunk, and upper extremities. The symptoms include painful skin papules, plaques, fever onset, and neutrophil infiltration. The condition can be diagnosed through clinical examination and skin biopsies. The management of the condition can be done through the use of corticosteroids and immunosuppressive agents. Maintaining a healthy lifestyle, regular health check-ups, and cancer screenings may help prevent the condition.